IP Library Granted Patent US 10,465,234
Granted Patent B2
US 10,465,234 · App. 16/169,801 · Granted Nov 5, 2019

Selective oxidation of 5-methylcytosine by TET-family proteins

Inventors: Anjana Rao (La Jolla, CA); Mamta Tahiliani (New York, NY); Kian Peng Koh (Jamaica Plain, MA); Suneet Agarwal (Belmont, MA); Aravind Iyer (Bethesda, MD)
Assignees: CHILDREN'S MEDICAL CENTER CORPORATION; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
C12Q1/6827C12N5/0018C12N5/0607C12N5/0637C12N5/0696C12N9/0071C12N15/873C12Q1/26C12Q1/6806C12Q1/6869C12Q1/6886G01N33/5011G01N33/5308G01N33/57426G01N33/57484G01N33/57496C12N2501/15C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2501/70C12N2501/71C12N2501/999C12N2506/1307C12N2506/1353C12N2510/00C12Q2521/531C12Q2522/10C12Q2537/164C12Q2600/154G01N2500/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,465,234
App. No.
16/169,801
Granted
Nov 5, 2019
Kind
B2
Abstract

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

Claims (11)

1. A method comprising: administering to a subject, an agent that modulates activity of an enzyme that mediates conversion of a methylated cytosine residue to a modified base, wherein said subject has a cancer or is at risk of developing said cancer, wherein said modified base comprises a hydroxymethylated cytosine residue and wherein said agent comprises a siRNA.

2. The method of claim 1 , wherein said subject is a mammal.

3. The method of claim 2 , wherein said methylated cytosine residue comprises a 5-methylcytosine.

4. The method of claim 2 , wherein said hydroxymethylated cytosine residue is a 5-hydroxymethylcytosine.

5. The method of claim 2 , wherein said cancer is leukemia.

6. The method of claim 5 , wherein said leukemia is myeloid leukemia.

7. The method of claim 2 , wherein said agent inhibits activity of said enzyme.

8. The method of claim 2 , wherein said enzyme comprises a TET family enzyme, functional TET family derivative, or a TET catalytically active fragment.

9. The method of claim 8 , wherein said TET family enzyme comprises TET1, TET2, TET3 or CXXC4.

10. The method of claim 8 , wherein said functional TET family derivative comprises SEQ ID NO: 1.

11. The method of claim 8 , wherein said TET catalytically active fragment comprises SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.

Assignments (7)
MERGER Recorded Feb 19, 2019
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 048373/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: IYER, ARAVIND
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 048373/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2019
From: RAO, ANJANA; TAHILIANI, MAMTA; KOH, KIAN PENG
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 048106/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2019
From: IYER, ARAVIND
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 049512/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2019
From: AGARWAL, SUNEET
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 048106/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2019
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 048106/0171 →
MERGER Recorded Jan 23, 2019
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 049517/0829 →
Continuity (8)
Continuation 15341344 · Nov 2, 2016
Continuation 15193796 · Jun 27, 2016
Continuation 13795739 · Mar 12, 2013
Continuation 13120861
Provisional Application 61121844 · Dec 11, 2008
Provisional Application 61100995 · Sep 29, 2008
Provisional Application 61100503 · Sep 26, 2008
Related Publication 20190048405A1 · Feb 14, 2019
Cited By (5)
US 12,291,742 US 12,331,346 US 12,338,489 US 12,467,082 US 12,630,866